Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR108 in Relapsed Advanced Lymphomas
NCT05984147Phase 1Recruiting
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Oct 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AG-636 in lymphoma, sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 1 year and 4 more. Started Oct 2023; status: recruiting.
02
Drugs
AG-636
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05984147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984147.